Blog Band - Page 263 of 299

20

Dec 2021

PharmaShots Interview: Boston Scientific’s Meghan Scanlon Shares Insight on the Completion of its $1.07B Lumenis Acquisition

In an interview with PharmaShots, Meghan Scanlon, Senior Vice President and President for Urology and Pelvic Health at Boston Scientific shares her views on the completion of its $1.07B acquisition of Lumenis surgical business Shots: Boston Scientific…

16

Dec 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2021

The US FDA has approved 6 NDAs and 1 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and…

15

Dec 2021

VIEWPOINTS

PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on the Data of AZP-3601 for Hypoparathyroidism

In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer at Amolyt Pharma shares his views on the data from the P-I trial of AZP-3601 for the treatment of Hypoparathyroidism Shots: The P-I trial evaluates…

14

Dec 2021

VIEWPOINTS

PharmaShots Interview: Abbott’s Neil Moat Shares Insight on the US FDA’s Approval of Epic Plus Tissue Valves for Mitral or Aortic Valve Replacement

In an interview with PharmaShots, Neil Moat, MD, DVP Medical Affairs, Chief Medical Officer at Abbott's shares his views on the Epic Plus Tissue Valves approval for the treatment of mitral or aortic valve replacement…

13

Dec 2021

VIEWPOINTS

PharmaShots Interview: AstraZeneca’s Alexander Bedenkov Shares Insight on First Virtual Events with Slush to Improve Patients Outcomes

In an interview with PharmaShots, Alexander Bedenkov, Vice President, Medical International Region & Global Health Innovation Hubs (A.Catalyst) Network Head at AstraZeneca shares his views on the First Virtual Events in collaboration with Slush to accelerate better health…

09

Dec 2021

VIEWPOINTS

PharmaShots Interview: Entasis Therapeutics’s Manos Perros Shares Insight on the Data of Sulbactam-Durlobactam (SUL-DUR) for Carbapenem-Resistant Acinetobacter Infections

In an interview with PharmaShots, Manos Perros shares his views on the data from the P-III (ATTACK) trial of sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant acinetobacter infections Shots: The P-III ATTACK trial evaluates SUL-DUR vs colistin in 207 patients…

08

Dec 2021

VIEWPOINTS

PharmaShots Interview: TFF Pharmaceuticals’s Glenn Mattes Shares Insights on the Thin Film Freezing Technology

In an interview with PharmaShots, Glenn Mattes, President, CEO, and Director at TFF Pharmaceuticals share his views on the thin film freezing technology for the development of vaccines and therapeutics against multiple infectious diseases including IPA Shots: The company…

07

Dec 2021

VIEWPOINTS

PharmaShots Interview: Coral Genomics’s Atray Dixit Shares Insights on the 2021 Innovation Challenge in Inflammatory Bowel Disease

In an interview with PharmaShots, Atray Dixit, Co-founder & CEO at Coral Genomics share his views on the winner of the $25K inflammatory bowel disease innovation challenge under the collaboration with Lyfebulb and Arena Shots:…

06

Dec 2021

VIEWPOINTS

PharmaShots Interview: Medidata’s Ben Schlatka Shares Insights on Agreement with Labcorp to Advance the Use of Medical-Grade Sensors

In an interview with PharmaShots, Ben Schlatka, Vice President, Digital Biomarker Solutions at Medidata share his views on the Agreement with Labcorp to expand decentralized clinical trial capabilities and digital biomarker discovery using Medidata Sensor…

02

Dec 2021

INSIGHTS+

Insights+ Key Biosimilars Events of November 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded…

PharmaShots Interview: Boston Scientific’s Meghan Scanlon Shares Insight on the Completion of its $1.07B Lumenis Acquisition

Insights+: The US FDA New Drug Approvals in November 2021

PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on the Data of AZP-3601 for Hypoparathyroidism

PharmaShots Interview: Abbott’s Neil Moat Shares Insight on the US FDA’s Approval of Epic Plus Tissue Valves for Mitral or Aortic Valve Replacement

PharmaShots Interview: AstraZeneca’s Alexander Bedenkov Shares Insight on First Virtual Events with Slush to Improve Patients Outcomes

PharmaShots Interview: Entasis Therapeutics’s Manos Perros Shares Insight on the Data of Sulbactam-Durlobactam (SUL-DUR) for Carbapenem-Resistant Acinetobacter Infections

PharmaShots Interview: TFF Pharmaceuticals’s Glenn Mattes Shares Insights on the Thin Film Freezing Technology

PharmaShots Interview: Coral Genomics’s Atray Dixit Shares Insights on the 2021 Innovation Challenge in Inflammatory Bowel Disease

PharmaShots Interview: Medidata’s Ben Schlatka Shares Insights on Agreement with Labcorp to Advance the Use of Medical-Grade Sensors

Insights+ Key Biosimilars Events of November 2021

Contact US

OUR INFORMATION

FOLLOW US